Albemarle opened lower at $91.42, compared with its previous close of $93.27. In the last trading session, the stock traded between $90.43 and $92.19. It showed a downward intraday trend.
return calculator
Time Period
An investment of $100 made 5 years ago in Albemarle is now worth
$ 36.27
resulting in a loss of
$ 63.73 (63.73%)
invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 15 Analysts
Buy
73.33%
Hold
26.67%
Sell
0%
Markets Today
Today's Change
$-2.43 (-2.60%)
Day High
$92.19
Day Low
$90.43
Day Open
$91.42
Prev Close
$93.27
Volume
6,59,941
1W Return
-1.84%
1M Return
-15.60%
3M Return
-20.22%
6M Return
-52.41%
1Y Return
-7.11%
Fundamentals
Market Cap ($ Mn)
10,720
PE Ratio
508.74
PB Ratio
2.02
PEG Ratio
-
ROE
-6.03%
ROCE
-2.30%
EPS (TTM)
$3.71
Investment Returns
1 Week
-1.84%
1 Month
-15.60%
3 Months
-20.22%
6 Months
-52.41%
9 Months
-49.73%
Financials
Quarterly
All values in $ Mn
1.2K
Dec 24
1.1K
Mar 25
1.3K
Jun 25
1.3K
Sep 25
1.4K
Dec 25
1.7K
Jun 26
Updates
20Oct
Truist Securities maintains Buy on Albemarle, cuts price target to $185
Truist Securities maintains Buy rating on Albemarle. Price target lowered from $225 to $185. Analyst Peter Osterland issued the revised rating.
10 days ago
15Oct
RBC cuts Albemarle price target to $129, maintains outperform rating
RBC Capital lowered Albemarle's price target to $129 from $157. The firm maintained its Outperform rating on the stock. Analyst Arun Viswanathan executed the valuation adjustment.
15 days ago
2Oct
Albemarle Corporation Q3FY26 Results: Earnings release set for Nov 4, 2026
Albemarle Corporation will release Q3FY26 earnings on November 4, 2026. Conference call scheduled for November 5, 2026, at 8 am EST. Results release occurs after NYSE market close. Webcast replay available post-event on investor relations site.
28 days ago
17Sep
Albemarle Q2FY26 Results: Adjusted EBITDA doubles to $858 million
Net sales rose 31% YoY to $1.7 billion, driven by higher pricing in Energy Storage and Specialties. Adjusted EBITDA more than doubled to $858 million, up 155% YoY. Specialties margin expanded 700 bps to 28% amid bromine market disruptions. Company generated $710 million in operating cash flow with >80% conversion. Raised full-year Specialties outlook for sales and EBITDA.
1mo ago
25Aug
JPMorgan Cuts Albemarle 2026-27 EBITDA Estimates on Weak Lithium Prices
JPMorgan cut Albemarle's 2026 adjusted EBITDA estimate by 14.4% to $2.88 billion. 2027 adjusted EBITDA estimate fell 18.4% to $2.93 billion on lower lithium price assumptions. Third-quarter adjusted EBITDA expected at $668 million, down from $858 million in Q2. Price target lowered to $140 for Dec 2027 from $160 for Dec 2026; rating remains Neutral. Greenbushes CGP3 plant delays push full production expectations to end of Q1FY27.
2mo ago
6Aug
Albemarie Latest Results: Sales guidance affirmed at $5.700B-$6.000B
Albemarie affirms FY26 sales guidance of $5.700B-$6.000B, falling short of the $6.334B estimate. The company maintains its previous outlook, indicating a cautious stance on future revenue performance relative to market expectations.
